NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

RVTY's strong product portfolio raises optimism about the stock.

QDEL's strong product portfolio raises optimism about the stock.

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Investors remain optimistic about Patterson Companies on the back of its broad product line.

STE's strong prospects in the healthcare business arm bode well for investors.

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.